Molecular indices of apoptosis after intermittent blood and crystalloid cardioplegia

Circulation. 2005 Aug 30;112(9 Suppl):I184-9. doi: 10.1161/CIRCULATIONAHA.104.526160.

Abstract

Background: We investigated whether intermittent blood and crystalloid cardioplegia differentially affect myocardial apoptosis and apoptosis gene-related proteins.

Methods and results: Rabbit hearts were perfused with Krebs-Henseleit buffer on a Langendorff apparatus. Control hearts (n=6) were perfused for 120 minutes without cardioplegic ischemia. Hearts were arrested for 60 minutes with warm (37 degrees C) crystalloid cardioplegia (iW-CCP) (n=8) or with warm blood cardioplegia (iW-BCP) (n=8) administered intermittently. In cold (0 to 4 degrees C) groups, hearts were arrested for 60 minutes with cold crystalloid cardioplegia (iC-CCP; n=8) or with cold blood cardioplegia (iC-BCP; n=6) administered intermittently. The hearts were reperfused for 30 minutes with Krebs-Henseleit buffer. iC-BCP significantly preserved the recovery of left ventricular and microvascular function compared with the other 3 experimental groups. There were no significant differences in total protein levels of caspase 3, Bcl-2, Bad, and Bax among the groups. iC-BCP significantly induced greater phosphorylation of Bad (5.6+/-0.8-fold) as compared with the other 3 groups (3.4+/-0.6-fold in iC-CCP, P<0.05; 2.5+/-0.3 in iW-BCP, P<0.05; and 1.4+/-0.2 in iW-CCP, P<0.01). iC-BCP induced less caspase 3 activation and apoptosis than the other 3 groups.

Conclusions: iC-BCP is superior to the other cardioplegic solutions in increasing the phosphorylation of Bad, inhibiting the activation of caspase 3, and preventing apoptosis. These effects of iC-BCP were associated with preserved left ventricular function and endothelium-dependent relaxation of coronary microvessels.

Publication types

  • Comparative Study
  • Evaluation Study
  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid / pharmacology
  • Adenosine Diphosphate / pharmacology
  • Animals
  • Apoptosis* / genetics
  • Biomarkers
  • Blood*
  • Cardioplegic Solutions / pharmacology*
  • Caspase 3
  • Caspases / analysis
  • Cold Temperature
  • Endothelium, Vascular / drug effects
  • Enzyme Activation / drug effects
  • Heart / drug effects*
  • Heart Arrest, Induced / adverse effects*
  • Heart Arrest, Induced / methods
  • In Situ Nick-End Labeling
  • Microcirculation / drug effects
  • Myocardial Reperfusion Injury / prevention & control*
  • Myocardium / chemistry*
  • Nitric Oxide Donors / pharmacology
  • Nitroprusside / pharmacology
  • Phosphorylation / drug effects
  • Potassium Compounds / pharmacology*
  • Protein Processing, Post-Translational / drug effects
  • Proto-Oncogene Proteins c-bcl-2 / analysis
  • Rabbits
  • Random Allocation
  • Temperature
  • Vasoconstrictor Agents / pharmacology
  • Vasodilator Agents / pharmacology
  • Ventricular Function, Left / drug effects
  • bcl-2-Associated X Protein / analysis
  • bcl-Associated Death Protein / analysis
  • bcl-Associated Death Protein / metabolism

Substances

  • Biomarkers
  • Cardioplegic Solutions
  • Nitric Oxide Donors
  • Potassium Compounds
  • Proto-Oncogene Proteins c-bcl-2
  • Vasoconstrictor Agents
  • Vasodilator Agents
  • bcl-2-Associated X Protein
  • bcl-Associated Death Protein
  • potassium cardioplegic solution
  • Nitroprusside
  • Adenosine Diphosphate
  • 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
  • Caspase 3
  • Caspases